{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:15:29Z","timestamp":1785842129106,"version":"3.56.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.ygyno.2009.09.011","type":"journal-article","created":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T04:17:01Z","timestamp":1254889021000},"page":"460-465","source":"Crossref","is-referenced-by-count":79,"title":["Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study"],"prefix":"10.1016","volume":"115","author":[{"given":"Martee L.","family":"Hensley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Dennis R.","family":"Scribner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jubilee","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"DeBernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Hartenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn K.","family":"McCourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Bosscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola A.","family":"Gehrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2009.09.011_bib1","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/cncr.2820710440","article-title":"Prognostic factors in early-stage uterine sarcoma: a Gynecologic Oncology Group Study","volume":"71","author":"Major","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2009.09.011_bib2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/0090-8258(92)90286-R","article-title":"Resection of pulmonary metastases from uterine sarcomas","volume":"45","author":"Levenback","year":"1992","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/gyno.1996.0220","article-title":"Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study","volume":"62","author":"Sutton","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib4","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1200\/JCO.2002.11.050","article-title":"Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial","volume":"20","author":"Hensley","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2008.03.010","article-title":"Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2008.02.024","article-title":"Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/0002-9378(92)91671-V","article-title":"Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"166","author":"Sutton","year":"1992","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ygyno.2003.11.023","article-title":"Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study","volume":"92","author":"Look","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib9","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1200\/JCO.2005.05.028","article-title":"Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study","volume":"23","author":"Garcia-Carbonero","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib10","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2001.19.5.1248","article-title":"Ecteinasidin-743: a marine-derived compound in advanced, pre-treated sarcoma patients\u2014preliminary evidence of activity","volume":"19","author":"Delaloge","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib11","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1200\/JCO.1991.9.11.1962","article-title":"Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study","volume":"9","author":"Thigpen","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00000421-199002000-00009","article-title":"Mitoxantrone in the treatment of advanced uterine sarcoma: a phase II trial of the Gynecologic Oncology Group","volume":"13","author":"Muss","year":"1990","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00000421-199804000-00010","article-title":"Amonafide in patients with leiomyosarcoma of the uterus: a phase II Gynecologic Oncology Group study","volume":"21","author":"Asbury","year":"1998","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1006\/gyno.1998.5080","article-title":"Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"70","author":"Rose","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF00175091","article-title":"A Phase II clinical trial of diazoquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"9","author":"Slayton","year":"1991","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ygyno.2009.09.011_bib16","first-page":"1303","article-title":"Phase II trial of etoposide in the management of advanced or recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"71","author":"Slayton","year":"1987","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.ygyno.2009.09.011_bib17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00000421-200008000-00009","article-title":"Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study","volume":"23","author":"Miller","year":"2000","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0090-8258(02)00136-1","article-title":"Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"89","author":"Gallup","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1006\/gyno.1999.5463","article-title":"Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"74","author":"Sutton","year":"1999","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ygyno.2007.01.019","article-title":"A Phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group Study","volume":"105","author":"McMeekin","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1006\/gyno.2001.6482","article-title":"Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group","volume":"84","author":"Smith","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib22","first-page":"276","article-title":"Vascular permeability factor gene expression in normal and neoplastic human ovaries","volume":"54","author":"Olson","year":"1994","journal-title":"Cancer. Res."},{"key":"10.1016\/j.ygyno.2009.09.011_bib23","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/jnci\/87.16.1237","article-title":"Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia","volume":"87","author":"Guidi","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2009.09.011_bib24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/(SICI)1097-0142(19960801)78:3<454::AID-CNCR12>3.0.CO;2-Y","article-title":"Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma","volume":"78","author":"Guidi","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2009.09.011_bib25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/gyno.1999.5418","article-title":"Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival","volume":"74","author":"Chen","year":"1999","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib26","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: A VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2009.09.011_bib27","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1200\/jco.2005.23.16_suppl.3029","article-title":"Safety and pharmacokinetics of intravenous VEGF-Trap in a phase I clinical trial of patients with advanced solid tumors","volume":"23","author":"Dupont","year":"2005","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib28","unstructured":"Investigator's Brochure SU011248 (December 2005). Pfizer, Inc. and Affiliates, New York, New York."},{"key":"10.1016\/j.ygyno.2009.09.011_bib29","unstructured":"Sill MW, Yothers G. A method for utilizing bivariate efficacy outcome measures to screen agents for activity in 2-stage phase II clinical trials, Technical Report 2006-08, Department of Biostatistics, University at Buffalo."},{"key":"10.1016\/j.ygyno.2009.09.011_bib30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib31","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2009.09.011_bib32","doi-asserted-by":"crossref","unstructured":"Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;27:3133\u201340.","DOI":"10.1200\/JCO.2008.20.4495"},{"key":"10.1016\/j.ygyno.2009.09.011_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.10533","article-title":"Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: results of a phase II trial","volume":"26","author":"Keohan","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.10535","article-title":"Phase II study of sunitinib malate (SM) in subjects with metastatic and\/or surgically unresectable non-GIST soft tissue sarcomas","volume":"26","author":"Vigil","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.09.011_bib35","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0959-8049(01)00398-7","article-title":"Progression-free rate as the principal end-point for phase II trials in soft tissue sarcoma","volume":"38","author":"Van Glabbeke","year":"2002","journal-title":"Eur. J. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809006829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809006829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T21:45:11Z","timestamp":1558561511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825809006829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0090825809006829"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.09.011","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}